Several critical factors including poor scientific planning, overlooking critical safety signals, and erroneous estimation of the potential of a drug candidate, play a key role in deciding if an early phase trial should be continued, staged, or suspended.
Enabled by a wide spectrum of experience across study types and designs, Algorics Biostatistics center of excellence is a highly focused group of expert biostatisticians leveraging your data and our technology to generate early evidence insights.
To learn more, download this brochure or drop us a line at hello@algorics.com